---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-068966"
form_type: "8-K"
ticker: "KNSA"
cik: "0001730430"
company_name: "Kiniksa Pharmaceuticals International, plc"
filed_at: "2023-06-07T23:59:59+00:00"
generated_at: "2026-06-14T05:56:38.921210+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Kiniksa annual meeting elects three directors, ratifies auditor, approves say-on-pay

## Summary
- Stephen R. Biggar, G. Bradley Cole, and Barry D. Quart elected as Class II directors with majority vote.
- PricewaterhouseCoopers LLP ratified as independent auditor for FY2023 (44.8M for, 23.6K against).
- Non-binding advisory vote on executive compensation approved (40.4M for, 1.3M against).
- All proposals passed; no annual meeting surprises.

## SEC filing metadata
- accession: 0001104659-23-068966
- form_type: 8-K
- ticker: KNSA
- cik: 0001730430
- company_name: Kiniksa Pharmaceuticals International, plc
- filed_at: 2023-06-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1730430/000110465923068966/0001104659-23-068966-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1730430/000110465923068966/tm2317945d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-068966
- JSON: https://secwatch.observer/filing/0001104659-23-068966.json
- Plain text: https://secwatch.observer/filing/0001104659-23-068966.txt

## Key facts
- Shareholder Votes
  Kiniksa Pharmaceuticals International, plc shareholders approved Advisory approval of the compensation of named executive officers as disclosed in the proxy statement at the 2023-06-06 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2023-06-06
  source text: Proposal 3 – The approval, on a non-binding, advisory basis, of the compensation of our named executive officers as disclosed in the Company’s proxy statement for the Annual Meeting pursuant to the applicable compensation disclosure rules of the Securities and Exchange Commission, including the compensation tables and narrative discussion. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 40,423,385 1,270,222 380,052 3,132,968
  evidence_url: https://www.sec.gov/Archives/edgar/data/1730430/000110465923068966/0001104659-23-068966-index.htm
- Shareholder Votes
  Kiniksa Pharmaceuticals International, plc shareholders approved Election of Stephen R. Biggar, G. Bradley Cole and Barry D. Quart as Class II Directors to serve until the 2026 Annual Meeting at the 2023-06-06 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-06-06
  source text: Proposal 1 – The election of Stephen R. Biggar, G. Bradley Cole and Barry D. Quart as Class II Directors to serve until the 2026 Annual Meeting of Shareholders and until their respective successors have been duly elected and qualified. Nominee Votes FOR Votes WITHHELD Broker Non-Votes Stephen R. Biggar 30,959,772 11,113,887 3,132,968 G. Bradley Cole 40,974,400 1,099,259 3,132,968 Barry D. Quart 40,953,831 1,119,828 3,132,968
  evidence_url: https://www.sec.gov/Archives/edgar/data/1730430/000110465923068966/0001104659-23-068966-index.htm
- Shareholder Votes
  Kiniksa Pharmaceuticals International, plc shareholders approved Appointment of PricewaterhouseCoopers LLP as auditor and ratification of their appointment for fiscal year 2023 at the 2023-06-06 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-06-06
  source text: Proposal 2 – The (a) appointment of PricewaterhouseCoopers LLP as the Company’s auditor until the close of the Company’s next Annual Meeting of Shareholders, (b) delegation to the Company’s Board of Directors, through the Audit Committee of the Board of Directors, of the authority to set the auditor’s remuneration for such period, and (c) ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 44,804,941 23,637 378,049 0
  evidence_url: https://www.sec.gov/Archives/edgar/data/1730430/000110465923068966/0001104659-23-068966-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.